<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2371">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 08, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04547140</url>
  </required_header>
  <id_info>
    <org_study_id>GC2006</org_study_id>
    <nct_id>NCT04547140</nct_id>
  </id_info>
  <brief_title>Study to Evaluate the Safety and Efficacy of Liquid Alpha1-Proteinase Inhibitor (Human) in Hospitalized Participants With Coronavirus Disease (COVID-19)</brief_title>
  <official_title>A Multicenter, Randomized, Double-blind, Placebo-Controlled, Parallel Group Study to Evaluate the Safety and Efficacy of Liquid Alpha1-Proteinase Inhibitor (Human) Plus Standard Medical Treatment (SMT) Versus Placebo Plus SMT in Hospitalized Subjects With COVID-19</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Grifols Therapeutics LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Grifols Therapeutics LLC</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to determine if liquid alpha1-proteinase inhibitor (human)&#xD;
      (liquid alpha1-PI) plus SMT can reduce the proportion of participants dying or requiring&#xD;
      intensive care unit (ICU) admission on or before Day 29 or who are dependent on high flow&#xD;
      oxygen devices or invasive mechanical ventilation on Day 29 versus placebo plus SMT in&#xD;
      hospitalized participants with COVID-19.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">January 2021</start_date>
  <completion_date type="Anticipated">September 2021</completion_date>
  <primary_completion_date type="Anticipated">April 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants Dying or Requiring ICU Admission</measure>
    <time_frame>Up to Day 29</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants Who are Dependent on High Flow Oxygen Devices or Invasive Mechanical Ventilation</measure>
    <time_frame>Day 29</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in National Early Warning Score (NEWS)</measure>
    <time_frame>Day 1 through Day 29</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Clinical Response as Assessed by: NEWS ≤ 2 Maintained for 24 hours</measure>
    <time_frame>Day 1 through Day 29</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Hospital Discharge</measure>
    <time_frame>Day 1 through Day 29</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of ICU Stay</measure>
    <time_frame>Up to Day 29</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Any Oxygen Use</measure>
    <time_frame>Day 1 through Day 29</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Mechanical Ventilation</measure>
    <time_frame>Up to Day 29</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change from Baseline in Ordinal Scale</measure>
    <time_frame>Day 1 through Day 29</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute Value Change from Baseline in Ordinal Scale</measure>
    <time_frame>Day 1 through Day 29</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants in Each Severity Category of the 7-point Ordinal Scale</measure>
    <time_frame>Day 15 and Day 29</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Sustained Normalization of Temperature</measure>
    <time_frame>Up to Day 29</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with Normalization of Fever</measure>
    <time_frame>Up to Day 29</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants who Develop Acute Respiratory Distress Syndrome (ARDS)</measure>
    <time_frame>Up to Day 29</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of Time to Clinical Progression</measure>
    <time_frame>Up to Day 29</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>COVID-19</condition>
  <arm_group>
    <arm_group_label>Liquid Alpha1-Proteinase Inhibitor+Standard Medical Treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive the first Intravenous (IV) infusion of liquid alpha1-proteinase inhibitor (human) (120 milligram per kilogram [mg/kg]), based on body weight on Day 1, followed by second liquid alpha1-proteinase inhibitor (human) dose of 120 mg/kg based on body weight, on Day 8. Participants will also receive all standard of care interventions while hospitalized, from Day 1 to Day 29.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo+Standard Medical Treatment</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants will receive IV infusions of 0.9% Normal Saline of commensurate volume to that of liquid alpha1-proteinase inhibitor as placebo on Day 1 and Day 8 Participants will also receive all standard of care interventions while hospitalized, from Day 1 to Day 29.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Liquid Alpha1-Proteinase Inhibitor (Human)</intervention_name>
    <description>Intravenous infusion 120 mg/kg</description>
    <arm_group_label>Liquid Alpha1-Proteinase Inhibitor+Standard Medical Treatment</arm_group_label>
    <other_name>Alpha1-proteinase inhibitor</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Intravenous infusion</description>
    <arm_group_label>Placebo+Standard Medical Treatment</arm_group_label>
    <other_name>0.9% Normal Saline</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Standard Medical Treatment</intervention_name>
    <description>SMT</description>
    <arm_group_label>Liquid Alpha1-Proteinase Inhibitor+Standard Medical Treatment</arm_group_label>
    <arm_group_label>Placebo+Standard Medical Treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Hospitalized male or female subject ≥ 18 years of age at time of screening who is&#xD;
             being treated for COVID-19. Subjects must be screened within 48 hours (≤ 48 hours) of&#xD;
             hospital admission.&#xD;
&#xD;
          2. Has laboratory-confirmed novel coronavirus {SARS-CoV-2} infection as determined by&#xD;
             qualitative polymerase chain reaction (PCR) (reverse transcriptase [RT]-PCR), or other&#xD;
             commercial or public health assay approved by regulatory authorities as a diagnostic&#xD;
             test for COVID-19 in any specimen during the current hospital admission prior to&#xD;
             randomization.&#xD;
&#xD;
          3. COVID-19 illness (symptoms) of any duration, including both of the following: a)&#xD;
             Radiographic infiltrates by imaging (chest X-Ray, computed tomography (CT) scan, etc.)&#xD;
             and/or clinical assessment (evidence of rales/crackles on exam) with peripheral oxygen&#xD;
             saturation by pulse oximetry (SpO2) &lt;94% on room air; b) Any one of the following&#xD;
             related to COVID-19: i. Ferritin &gt; 400 nanogram per milliliter (ng/mL), ii. lactate&#xD;
             dehydrogenase (LDH) &gt; 300 units per liter (U/L), iii. D-Dimers &gt; reference range, or&#xD;
             iv. C-reactive protein (CRP) &gt; 40 milligram per liter (mg/L).&#xD;
&#xD;
          4. Subject provides informed consent prior to initiation of any study procedures.&#xD;
&#xD;
          5. Female subjects of childbearing potential (and males with female partners of&#xD;
             childbearing potential) must agree to use of acceptable contraception methods during&#xD;
             study (example, oral, injectable, or implanted hormonal methods of contraception,&#xD;
             placement of an intrauterine device or intrauterine system, condom or occlusive cap&#xD;
             with spermicidal foam/gel/film/cream/suppository, male sterilization, or true&#xD;
             abstinence) throughout the study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Subjects requiring invasive mechanical ventilation or ICU admission or with partial&#xD;
             pressure of arterial oxygen/ fraction of inspired oxygen (PaO2/FIO2) ≤ 150 mmHg (i.e.,&#xD;
             arterial oxygen in millimeter of mercury (mmHg) divided by fraction inspired oxygen&#xD;
             concentration [example, 0.21 for room air]).&#xD;
&#xD;
          2. Clinical evidence of any significant acute or chronic disease that, in the opinion of&#xD;
             the investigator, may place the subject at undue medical risk.&#xD;
&#xD;
          3. The subject has had a known serious anaphylactic reaction to blood, any blood-derived&#xD;
             or plasma product, or known selective immunoglobulin A (IgA) deficiency with anti-IgA&#xD;
             antibodies.&#xD;
&#xD;
          4. A medical condition in which the infusion of additional fluid is contraindicated&#xD;
             (example, decompensated congestive heart failure or renal failure with fluid&#xD;
             overload). This includes currently uncontrolled congestive heart failure New York&#xD;
             Heart Association Class III or IV stage heart failure.&#xD;
&#xD;
          5. Shock that is unresponsive to fluid challenge and/or multiple vasopressors and&#xD;
             accompanied by multiorgan failure considered not able to be reversed by the Principal&#xD;
             Investigator.&#xD;
&#xD;
          6. Known alpha-1 antitrypsin deficiency for which the subject is already receiving&#xD;
             alpha1-proteinase inhibitor augmentation therapy.&#xD;
&#xD;
          7. Women who are pregnant or breastfeeding. Female subjects of child-bearing potential&#xD;
             must have a negative test for pregnancy blood or urine human chorionic gonadotropin&#xD;
             (HCG)-based assay at screening/baseline visit.&#xD;
&#xD;
          8. Subjects for whom there is limitation of therapeutic effort such as &quot;Do not&#xD;
             resuscitate&quot; status.&#xD;
&#xD;
          9. Currently participating in another interventional clinical trial with investigational&#xD;
             medical product or device.&#xD;
&#xD;
         10. Subjects previously requiring long-term oxygen therapy (home oxygen therapy).&#xD;
&#xD;
         11. History (within the last 2 years) of myocardial infarction, unstable angina, stroke or&#xD;
             transient ischemic attacks, pulmonary embolism or deep venous thrombosis&#xD;
&#xD;
         12. Subject has medical condition (other than COVID-19) that is projected to limit&#xD;
             lifespan to ≤ 1 year&#xD;
&#xD;
         13. Systolic blood pressure &lt; 100 mm Hg or &gt; 160 mm Hg (uncontrolled hypertension) at the&#xD;
             time of Screening&#xD;
&#xD;
         14. Alanine aminotransferase (ALT) ≥ 2 times the upper limit of normal (ULN)&#xD;
&#xD;
         15. Any elevation of total bilirubin at the time of Screening&#xD;
&#xD;
         16. Estimated glomerular filtration rate (eGFR) &lt; 45 mL/min (or subject is dependent on&#xD;
             dialysis/renal replacement therapy) at the time of Screening&#xD;
&#xD;
         17. Hemoglobin &lt; 10 g/dL at the time of Screening&#xD;
&#xD;
         18. Absolute neutrophil count &lt; 1000/mm3 at the time of Screening&#xD;
&#xD;
         19. Platelet count &lt; 75,000/mm3 at the time of Screening&#xD;
&#xD;
         20. Subject has history of drug or alcohol abuse within the past 24 months&#xD;
&#xD;
         21. Subject is unwilling to commit to follow-up visits&#xD;
&#xD;
         22. Known history of prothrombin gene mutation 20210, homozygous Factor V Leiden&#xD;
             mutations, antithrombin III deficiency, protein C deficiency, protein S deficiency or&#xD;
             antiphospholipid syndrome&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Susan Sorrells</last_name>
    <phone>919-316-6582</phone>
    <email>susan.sorrells@grifols.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Elsa Mondou</last_name>
    <phone>919-316-2079</phone>
    <email>elsa.mondou@grifols.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Birmingham VA</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35233</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mike Wells, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHI Health Center</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68102</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bryan Krajicek, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Columbia University Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Monica Goldklang, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Utah</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84108</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cheryl Pirozzi, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>AngioCor Blumenau</name>
      <address>
        <city>Blumenau</city>
        <state>Santa Catarina</state>
        <zip>89020-430</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Adrian Kormann, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Sao Jose</name>
      <address>
        <city>Criciúma</city>
        <state>Santa Catarina</state>
        <zip>88811-500</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Felipe Dal Pizzol, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital das Clinicas da Faculdade de Medicina de Botucatu</name>
      <address>
        <city>Botucatu</city>
        <state>São Paulo</state>
        <zip>18618-686</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ricardo Almeida, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Alemao Oswaldo Cruz</name>
      <address>
        <city>São Paulo</city>
        <zip>01327-001</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Victor Sato, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Brazil</country>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>September 10, 2020</study_first_submitted>
  <study_first_submitted_qc>September 10, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 14, 2020</study_first_posted>
  <last_update_submitted>January 13, 2021</last_update_submitted>
  <last_update_submitted_qc>January 13, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 14, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Coronavirus Disease</keyword>
  <keyword>Severe acute respiratory syndrome coronavirus 2</keyword>
  <keyword>SARS-CoV-2</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alpha 1-Antitrypsin Deficiency</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Protease Inhibitors</mesh_term>
    <mesh_term>Alpha 1-Antitrypsin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

